Evidence map›Paper›PMID 34686753›Full record

ArticleScientific reports2021

Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant.

Martin Leníček, Václav Šmíd, Petr Pajer, Anna Nazarova, Karel Dvořák, Iva Subhanová, Radan Brůha, Libor Vítek

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Martin LeníčekInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Kateřinská 32, 12108, Prague, Czech Republic. martin.lenicek@lf1.cuni.cz.
Václav Šmíd4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, U Nemocnice 499/2, 12808, Prague, Czech Republic.
Petr PajerDepartment of Microbiology and Biological Defence Research, Military Health Institute Prague, Tychonova 1, 16001, Prague, Czech Republic.
Anna NazarovaInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Kateřinská 32, 12108, Prague, Czech Republic.
Karel Dvořák4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, U Nemocnice 499/2, 12808, Prague, Czech Republic.
Iva SubhanováInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Kateřinská 32, 12108, Prague, Czech Republic.
Radan Brůha4th Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, U Nemocnice 499/2, 12808, Prague, Czech Republic.
Libor VítekInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Kateřinská 32, 12108, Prague, Czech Republic.
Charles University · CZGeneral University Hospital in Prague · CZKrajská Nemocnice Liberec · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The patatin-like phospholipase domain containing 3 (PNPLA3) gene (viz. its I148M variant) is one of the key players in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We have identified a novel insertion/deletion variant of 1114 bp, localized in the second intron of the PNPLA3 gene, which corresponds to the 3' terminal sequence of the long-interspersed element (LINE-1). DNA analysis of 122 NAFLD patients and 167 control subjects as well as RNA analysis of 19 liver biopsies revealed that the novel variant is very common (frequency = 0.41), fully linked to the clinically important I148M variant, and clinically silent. Although the LINE-1 insertion does not seem to have any biological effect, it can impede genotyping of the I148M variant. If insertion prevents the attachment of the diagnostic primer, then the non-insertion allele will be selectively amplified; and thus the frequency of the 148M "risk" allele will be significantly overestimated due to the complete linkage of the LINE-1 insertion and the 148I allele of the PNPLA3 gene. Therefore, our findings underline the importance of careful design and consistent documentation of the methodology, including primer sequences. Critical revisions of the results of some studies that have already been reported may therefore be needed.

Indexed as

AcyltransferasesAllelesGenetic Predisposition to DiseaseGenotypeHumansLiverLong Interspersed Nucleotide ElementsNon-alcoholic Fatty Liver DiseasePhospholipases A2, Calcium-IndependentPolymorphism, Single NucleotideAcyltransferasesPhospholipases A2, Calcium-IndependentPNPLA3 protein, human

Identifiers

PMID34686753
PMCPMC8536765
OpenAlexW3205536622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.